Skip to main content
. 2022 Sep 26;12:917353. doi: 10.3389/fonc.2022.917353

Figure 1.

Figure 1

Kaplan-Meier curve of PFS (A) and OS (B) in the general population. Kaplan-Meier curve of PFS (C) and OS (D) in the regorafenib plus sintilimab(RS), and fruquintinib plus sintilimab(FS) group.